



MMI 291 Seminar Series

Current Theme: Interdisciplinary Research
Fall Quarter 2021 – CRN 41611

Friday Seminar – 12:10-1 PM

“To Live or Let Die: Unraveling Charged Interactions for the Next Effective Cancer Therapeutic Design”

Research / Bio

Dr. Tushir-Singh earned his undergraduate and master's degree from Delhi University and Panjab University in India. His Ph.D. research focused on the "Rho family of small GTPases in epithelial to mesenchymal transitions" at the University of Notre Dame, IN. He performed his postdoctoral studies at HHMI and RNA Therapeutic Institute with Dr. Phillip D. Zamore. His postdoc work focused on the biochemistry and mechanism of piRNA cleavage by Piwi Argonaute protein. After postdoctoral studies, he worked at Abbvie Biologics and Boehringer Ingelheim Biotherapeutics as a Senior Scientist and Principal Scientist in antibody discovery divisions. He joined the University of Virginia Cancer Center as an Assistant Professor of Biochemistry and Molecular Genetics in 2015. His research aims to understand and target the differential cancer immunotherapy responses in solid vs. liquid cancers. He utilizes protein engineering and antibody conjugates-based approaches to investigate the mechanisms of cancer cell signaling, tumor immune evasion, and tumor cell death.

Publications

Lum LG, **Tushir-Singh J.** Arming "old guards" with "new dual-targeting weapons". *Cancer Cell* (2021) May 10;39(5):604-606.


Mondal T, Shivange G, Urbanek K, Rachisan G.T., Batista M, Talwar P, Lysterly E, Mosavian R, Stack S, Bhatnagar S, and **Tushir-Singh, J.** Unexpected Immune Evasion in TNBC, Ovarian and other solid tumors by DR5 Agonist Antibodies. *EMBO Molecular Medicine* (2021) 13(3): e12716.

Shivange G, Mondal T, and **Tushir-Singh J.** Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody. *J. Vis. Exp.* (2020), e60727

Shivange G, Urbanek K, Przanowski P, Perry J, Haggert R, Jones J, Koska C, Landen CN, Mayo M, Ravichandran KS, Bhatnagar S and **Tushir-Singh J.** A Single Agent Dual Specificity Targeting of FOLR1 and TRAIL-R2 as an Effective Strategy for Ovarian Cancer. *Cancer Cell* (2018) Aug 13;34(2):331-345.e11.



Oct
15



Jogender Tushir-Singh, Ph.D.
Associate Professor
and DoD Ovarian Cancer Academy
Early Career Investigator
Department of Medical Microbiology and
Immunology
University California Davis

**Oct 15, 2021
12:10 – 1 PM
ZOOM Meeting**

Medical Microbiology
& Immunology
School of Medicine

Seminar Contact:
Autumn Vega
530-752-9401
avega@ucdavis.edu

We hope to see you there!